Vysis files 510(k)s for CML, bone marrow transplant tests, lands broad FISH patent.
This article was originally published in The Gray Sheet
Executive Summary
VYSIS 510(K)s FOR CEP CML, BONE MARROW TRANSPLANT MONITORING TESTS utilizing fluorescence in situ hybridization technology were submitted to FDA July 31 and Aug. 31, respectively, the company says. Both products are chromosome enumeration probes designed to evaluate and count specific chromosomes in metaphases and interphase nuclei. CEP 8, the prognostic indicator and monitoring probe for chronic myelogenous leukemia, detects copies of chromosome 8; the presence of a third copy indicates a poor prognosis. CEP XY monitors sex chromosomes in the blood of a patient following a bone marrow transplant from a patient of the opposite sex.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.